股息初学者
liked
2
股息初学者
commented on
股息初学者
commented on
$WELL CHIP GROUP(5325.MY$ Fangyuan Group has many very good businesses in Singapore
Translated
2
4
$PLINTAS(5320.MY$ It only took off the company's money soon after it went public! The upper floors inside are very dark
Translated
2
股息初学者
commented on
Co-branded TaurX's new drug Genting expects approval as soon as possible
$GENTING(3182.MY$ Genting expects that new drugs for dementia will soon be approved by official agencies in various countries, including the US Food and Drug Administration (FDA), with a 20% shareholding company, TaurX.
In response to questions at a press conference on Thursday, Genting Chairman and CEO Tan Sri Lam Cathay said that Genting is only a small operator in the pharmaceutical field, not comparable to many pharmaceutical giants, but the company is determined to bring cheaper and more effective drugs to the world.
“In addition to its core business, Genting is also undertaking some new projects, and TaurX's new drug is one of them. We expect good news soon in terms of official approval of this new drug.”
Genting President, Chief Operating Officer and Executive Director Dato' Sri Chan Kwang-han pointed out that many activities are currently underway, and the official approval process for new drugs is underway, particularly the UK Medicines and Healthcare Products Regulatory Authority (MHRA).
“As for the FDA, we are awaiting their feedback and the process is still ongoing.”
Chen Guanghan stressed that only the official agency knows what stage the approval process for the new TaurX drug has reached; everything has to be decided by the other party.
According to clinical test results announced in March of this year, TaurX said that its new drug has lasting effects in fighting dementia and has no sequelae of cerebral hemorrhage. Compared with other drugs for dementia, the price is also lower.
Source: South Seas...
$GENTING(3182.MY$ Genting expects that new drugs for dementia will soon be approved by official agencies in various countries, including the US Food and Drug Administration (FDA), with a 20% shareholding company, TaurX.
In response to questions at a press conference on Thursday, Genting Chairman and CEO Tan Sri Lam Cathay said that Genting is only a small operator in the pharmaceutical field, not comparable to many pharmaceutical giants, but the company is determined to bring cheaper and more effective drugs to the world.
“In addition to its core business, Genting is also undertaking some new projects, and TaurX's new drug is one of them. We expect good news soon in terms of official approval of this new drug.”
Genting President, Chief Operating Officer and Executive Director Dato' Sri Chan Kwang-han pointed out that many activities are currently underway, and the official approval process for new drugs is underway, particularly the UK Medicines and Healthcare Products Regulatory Authority (MHRA).
“As for the FDA, we are awaiting their feedback and the process is still ongoing.”
Chen Guanghan stressed that only the official agency knows what stage the approval process for the new TaurX drug has reached; everything has to be decided by the other party.
According to clinical test results announced in March of this year, TaurX said that its new drug has lasting effects in fighting dementia and has no sequelae of cerebral hemorrhage. Compared with other drugs for dementia, the price is also lower.
Source: South Seas...
Translated
![Co-branded TaurX's new drug Genting expects approval as soon as possible](https://sgsnsimg.moomoo.com/sns_client_feed/103267505/20240621/7e36b95c57fc40d643114e9dc4ed0cca.jpg/thumb?area=104&is_public=true)
22
3
股息初学者
voted
U.S. unemployment claims in the week ended June 1 remained below last year's level even amid a slight uptick, data from the Department of Labor showed Thursday morning.
Seasonally adjusted initial jobless claims rose 8,000 to 229,000 from the previous week's upwardly revised level. That compares with 255,000 claims filed in the same week a year ago, the Labor Department said in a press release.
The data came days after th...
Seasonally adjusted initial jobless claims rose 8,000 to 229,000 from the previous week's upwardly revised level. That compares with 255,000 claims filed in the same week a year ago, the Labor Department said in a press release.
The data came days after th...
![US jobless claims stayed below last year's level even amid a slight uptick](https://ussnsimg.moomoo.com/sns_client_feed/73842169/20240606/1717683118654-274a4dc6c3.png/thumb?area=100&is_public=true)
3